Guoliang Xun

This inventor holds 7 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignee: Novartis Ag. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guoliang Xun. Retrieved from https://idiyas.com/inventor/guoliang-xun

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 7)

% Patents Active = 57.1

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 2 (Patent Applications = 16)

Average Co-Inventor Count = 7.1

ph-index = 2

Forward Citations = 16(Granted Patents)

Location History:

Jiangsu Province, CN (2013)
Shanghai, CN (2020)
Taicang, CN (2013 - 2022)

Company Filing History:

7 out of 3,975

Novartis Ag

patents

Years Active: 2013-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12312353 - Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents (2025-05-27),

2. 11420970 - Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents (2022-08-23),

3. 10604502 - Substituted 5-cyanoindole compounds and uses thereof (2020-03-31),

4. 10590079 - Cyano-substituted indoles as LSD1 inhibitors (2020-03-17),

5. 8507676 - Heterocyclic oxime compounds (2013-08-13),

6. 8497368 - Heterocyclic hydrazone compounds (2013-07-30),

7. 8410264 - Heterocyclic oxime compounds (2013-04-02),

Title: Guoliang Xun: Pioneering Innovations in Anti-Cancer Solutions

Introduction

Guoliang Xun is a prominent inventor based in Taicang, China, recognized for his significant contributions to the field of pharmaceutical research. With a total of seven patents to his name, Xun is at the forefront of developing innovative solutions for cancer treatment.

Latest Patents

Among his latest inventions, Guoliang Xun has made notable strides with his work on "Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents." This patent presents a compound that has the potential to inhibit NSD2, offering new avenues for anti-cancer therapies. The innovative formula has garnered attention within the scientific community, highlighting its significance in the ongoing battle against cancer.

Career Highlights

Guoliang Xun is currently associated with Novartis AG, a leading global healthcare company. His work in the pharmaceutical sector emphasizes innovation and research dedicated to improving patient outcomes through effective drug development. Throughout his career, Xun has demonstrated an unwavering commitment to scientific advancement and therapeutic innovation.

Collaborations

Collaboration is key in the world of research, and Guoliang Xun is fortunate to work alongside esteemed colleagues such as Feng He and Qitao Xiao. Together, these inventors contribute to a dynamic research environment that fosters creativity and the sharing of ideas, ultimately pushing the boundaries of conventional cancer treatments.

Conclusion

Guoliang Xun’s innovative work and dedication to developing new anti-cancer agents underscore the vital role of inventors in the advancement of medicine. Through his patents and collaborations, he highlights the importance of research in finding solutions to pressing health challenges, paving the way for future breakthroughs in cancer therapy.

Profile summary based on public USPTO records.